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Inorganic arsenic is a natural element of the
earth crust. It enters drinking water supplies
from natural deposits or from agricultural and
industrial practices. Long-term exposure to
arsenic in groundwater has been related to ele-
vated risks of cancer of the bladder, lungs,
skin, kidneys, and liver (Chen CJ et al. 1988;
Chen CL et al. 2004; Morales et al. 2000;
Tseng WP 1989); diabetes (Tseng CH et al.
2002; Wang SL et al. 2003); cardiovascular
disease (CVD) (Chen CJ et al. 1995, 1996;
Chiou et al. 1997; Tseng CH et al. 2003;
Wang CH et al. 2002); adverse pregnancy
outcomes (Ahmad et al. 2001; von Ehrenstein
et al. 2006); and a decrease in children’s intel-
lectual function (von Ehrenstein et al. 2007;
Wasserman et al. 2004).
Evidence of high-level arsenic exposure
(> 200 µg/L) on vascular disease is largely
based on a series of epidemiologic studies in
southwestern Taiwan (Ch’i and Blackwell
1968; Chen CJ et al. 1996; Chiou et al. 1997;
Tseng CH et al. 2003; Wang CH et al.
2002), collectively suggesting that arsenic
exposure induces atherosclerosis, the most
common pathologic process underlying CVD
that often manifests clinically as coronary 
disease, stroke, or peripheral arterial disease.
However, neither a biological mechanism nor
the effect of low-level exposure is clear. More
recently, in a cross-sectional analysis, we
found a positive association between arsenic
exposure and high pulse pressure (Chen Y
et al. 2006a), an indicator of arterial stiffness
that is associated with an increased risk of
atherosclerosis (Dart and Kingwell 2001;
Safar et al. 2003). Prospective studies of CVD
risk factors, biomarkers, and clinical end
points in populations exposed to a wide range
of arsenic levels are therefore a public health
research priority.
Experimental studies have suggested that
arsenic increases the production of reactive
oxygen species such as hydrogen peroxide
(Barchowsky et al. 1999; Chen YC et al.
1998) and hydroxyl radicals (Wang TS et al.
1996), which may then lead to oxidative
stress. In turn, arsenic-induced oxidative
stress may mediate gene expression, inﬂam-
matory responses, or impaired nitric oxide
homeostasis (Simeonova and Luster 2004).
These events may ultimately lead to endothe-
lial dysfunction, which disrupts the balance
in vasomotor tone between relaxation and
contraction and increases the risk for vascular
diseases such as hypertension and athero-
sclerosis (Kumagai and Pi 2004).
Circulating markers of systemic inflam-
mation and endothelial dysfunction, such as
soluble intercellular adhesion molecule-1
(sICAM-1) and soluble vascular adhesion
molecule-1 (sVCAM-1) have been shown to
predict future CVD (Blankenberg et al.
2001; Hwang et al. 1997; Ridker et al. 1998,
2000). Expression of ICAM-1 and VCAM-1
in human umbilical vein endothelial cells was
higher in cells stimulated with arsenic than in
those without arsenic (Hou et al. 2005).
Treatment of mice with arsenic trioxide was
associated with a clear increase in expression
of ICAM-1 and VCAM-1 (Griffin et al.
2000). However, epidemiologic studies are
needed to examine these associations in
human populations exposed to arsenic at
doses relevant to environmental levels of
arsenic exposure.
We evaluated the effects of arsenic expo-
sure on plasma levels of sICAM-1 and
sVCAM-1 among 115 individuals participat-
ing in a 2 × 2 randomized, placebo-controlled,
double-blind trial of vitamin E and selenium
supplementation in Araihazar, Bangladesh.
Because of the availability of plasma and urine
samples at baseline and at follow-up, we were
also able to evaluate the effects of changes in
arsenic exposure, as well as the effects of vita-
min E and selenium supplementation, on
changes in plasma sICAM-1 and sVCAM-1.
Methods
Study participants. The study population
consists of individuals with arsenic-related
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BACKGROUND: Epidemiologic studies of cardiovascular disease risk factors and appropriate bio-
markers in populations exposed to a wide range of arsenic levels are a public health research priority.
OBJECTIVE: We investigated the relationship between inorganic arsenic exposure from drinking
water and plasma levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular
adhesion molecule-1 (sVCAM-1), both markers of endothelial dysfunction and vascular inﬂamma-
tion, in an arsenic-exposed population in Araihazar, Bangladesh.
METHODS: The study participants included 115 individuals with arsenic-related skin lesions partici-
pating in a 2 × 2 randomized, placebo-controlled, double-blind trial of vitamin E and selenium sup-
plementation. Arsenic exposure status and plasma levels of sICAM-1 and sVCAM-1 were assessed
at baseline and after 6 months of follow-up.
RESULTS: Baseline well arsenic, a long-term measure of arsenic exposure, was positively associated
with baseline levels of both sICAM-1 and sVCAM-1 and with changes in the two markers over
time. At baseline, for every 1-µg/L increase in well arsenic there was an increase of 0.10 ng/mL
[95% confidence interval (CI), 0.00–0.20] and 0.33 ng/mL (95% CI, 0.15–0.51) in plasma
sICAM-1 and sVCAM-1, respectively. Every 1-µg/L increase in well arsenic was associated with a
rise of 0.11 ng/mL (95% CI, 0.01–0.22) and 0.17 ng/mL (95% CI, 0.00–0.35) in sICAM-1 and
sVCAM-1 from baseline to follow-up, respectively, in spite of recent changes in urinary arsenic as
well as vitamin E and selenium supplementation during the study period.
CONCLUSIONS: The ﬁndings indicate an effect of chronic arsenic exposure from drinking water on
vascular inﬂammation that persists over time and also suggest a potential mechanism underlying
the association between arsenic exposure and cardiovascular disease.
KEY WORDS: arsenic, Bangladesh, cardiovascular disease, epidemiology, environmental epidemiol-
ogy, endothelial dysfunction, vascular inflammation. Environ Health Perspect 115:1415–1420
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double-blind placebo-controlled trial of vita-
min E and selenium. The trial was primarily
designed to evaluate the effects of vitamin E
and selenium in improving skin lesions.
Details of the study have been presented else-
where (Verret et al. 2005). Brieﬂy, a total of
124 participants with arsenic-related skin
lesions were recruited from the Health Effects
of Arsenic Longitudinal Study (HEALS), a
prospective cohort study with 11,746 partici-
pants in Araihazar, Bangladesh (Ahsan et al.
2006a). They were randomized to one of four
treatment arms: vitamin E (400 mg racemic
α-tocopherol), selenium (200 µg L-seleno-
methionine), vitamin E and selenium (combi-
nation), or placebo. Eligibility criteria
included participation in the parent HEALS,
20–65 years of age, and clinical signs of
arsenic-induced skin lesions on at least 10% of
the body surface area. The first 124 subjects
who fulfilled the eligibility criteria and gave
oral informed consent were recruited. The
study was approved by the Columbia
University Institutional Review Board and the
Bangladesh Medical Research Council Ethical
Committee.
At baseline, participants underwent a full
physical examination. Study medication was
taken once daily with water, at the same time
of day for 6 months (26 weeks). The field
research assistants visited each participant
every 2 weeks to resupply study medication,
assess compliance, and record any adverse
events. At the end of the 6-month treatment
period, study subjects were again visited by the
study physician for a follow-up visit at which
all baseline study procedures were repeated.
A blood and a spot urine sample were
taken at baseline and at the end of the treat-
ment period. Whole venous blood samples
were collected in 10-mL EDTA Vacutainer
tubes. A spot urine sample was collected in
50-mL acid-washed tubes. Both blood and
urine samples were kept in portable 4°C cool-
ers immediately after collection and were
processed within 2–8 hr at the end of the day
in the study ofﬁce located in Dhaka city. The
blood samples were spun in a table-top cen-
trifuge to separate the cells and plasma and
stored at –80°C until shipment to Columbia
University on dry ice within 1–2 months.
Upon receipt, both urine and blood samples
were stored at –80°C until analysis.
The present analysis included 115 partici-
pants who provided blood and urine samples
at both baseline and follow-up.
Skin lesion diagnosis. Arsenic-related skin
lesions have a short latency period and may
appear within a few years of exposure. The
typical natural progression of the disease starts
with hyperpigmentation of the skin, known as
“melanosis,” followed by (or in parallel with)
a characteristic bilateral thickening of the
palms and soles known as “hyperkeratosis,”
which often includes nodular protrusions.
Trained physicians completed a comprehen-
sive physical examination at baseline and 
follow-up visits. Physicians were blind to
information on the arsenic level in partici-
pants’ drinking wells. Details of the clinical
examination protocol for skin lesion diagnosis
have been described previously (Ahsan et al.
2006a). We instituted a structured protocol
adapting the method for quantitative assess-
ment of the extent of body surface involve-
ment in burn patients. The present analysis
included 115 conﬁrmed cases of skin lesions;
72 participants had only melanosis, and the
remaining 43 had both hyperkeratosis and
melanosis.
Arsenic exposure measurements. Total uri-
nary arsenic concentration was measured by
graphite furnace atomic absorption spectrom-
etry using a Perkin-Elmer AAnalyst 600
graphite furnace system (PerkinElmer,
Wellesley, MA) in the Columbia University
Trace Metals Core Laboratory, as described
previously (Nixon et al. 1991). Urinary crea-
tinine levels were analyzed by a colorimetric
Sigma Diagnostics Kit (Sigma, St. Louis,
MO) as described by Slot (1965). We also
calculated changes in urinary arsenic from
baseline to follow-up. The concentration of
total arsenic in urine has previously been
shown to be an excellent biomarker of arsenic
exposure in this cohort (Hall et al. 2006).
Therefore, we consider changes in urinary
arsenic concentration to be a good measure of
changes in arsenic exposure over time. After
the baseline recruitment of the parent cohort
study, an arsenic mitigation program including
Chen et al.
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Table 1. Distributions of demographic, lifestyle, and antioxidant treatment assignments according to well arsenic concentrations in the study population.
Baseline well arsenic concentration levels in quartiles
Q1 Q2 Q3 Q4
Overall (3–96 µg/L) (97–230 µg/L) (231–381 µg/L) (382–864 µg/L) p-Valuea
Total no. 115 29 29 29 28
Age in years (mean ± SD) 46.8 ± 9.0 48.9 ± 9.5 48.7 ± 8.2 45.3 ± 8.2 44.4 ± 9.4 0.12
BMI (mean ± SD) 18.9 ± 2.5 18.9 ± 2.5 19.3 ± 2.9 18.8 ± 2.2 18.8 ± 2.5 0.85
Education in years (mean ± SD) 2.4 ± 3.3 2.3 ± 3.2 2.3 ± 2.9 2.0 ± 3.3 3.1 ± 3.9 0.59
Male (%) 88.7 89.7 89.7 89.7 85.7 0.95
Smoking status (%)
Past smokers 26.1 20.7 17.2 27.6 39.3
Current smokers 48.7 62.1 58.6 41.4 32.1 0.25
Treatment assignment (%)
Placebo 25.2 24.1 24.1 24.1 28.6 0.98
Vitamin E only 25.2 27.6 17.3 27.6 28.6
Selenium only 24.4 24.1 27.6 20.7 25.0
Vitamin E and selenium 25.2 24.1 31.0 27.6 17.9
Skin lesion types (%)
Melanosis only 62.6 68.9 82.8 62.1 35.7 < 0.01
Hyperkeratosis and melanosis 37.4 31.0 17.2 37.9 64.3
Treatment duration in weeks (mean ± SD) 26.5 ± 0.6 26.5 ± 0.5 26.6 ± 0.6 26.4 ± 0.6 26.6 ± 0.6 0.48
Well use duration of baseline well (mean ± SD) 9.1 ± 6.2 9.3 ± 5.8 7.6 ± 4.6 10.0 ± 6.0 9.7 ± 8.1 0.46
Switched to other wells (%) 49.6 34.5 37.9 55.2 71.4 0.02
Baseline urinary arsenic (µg/g creatinine) 336.4 ± 313.8 263.2 ± 213.2 266.3 ± 173.8 450.5 ± 430.1 366.8 ± 345.7 0.05
Follow-up urinary arsenic (µg/g creatinine) 263.1 ± 348.5 207.8 ± 144.3 183.8 ± 149.8 298.5 ± 317.4 365.9 ± 584.2 0.17
Changes in urinary arsenic (µg/g creatinine) –73.3 ± 291.4 –55.4 ± 101.8 –82.5 ± 1119.5 –151.9 ± 179.5 –0.93 ± 535.8 0.26
Plasma levels (ng/mL)
sICAM-1 at baseline 397.5 ± 110.7 399.2 ± 95.3 401.1 ± 136.8 389.7 ± 110.3 399.9 ± 101.3 0.41
sICAM-1 at follow-up 403.3 ± 152.1 401.8 ± 91.3 387.4 ± 130.6 378.7 ± 112.4 446.7 ± 235.2 0.04
sVCAM-1 at baseline 636.9 ± 201.1 597.4 ± 162.3 603.5 ± 165.7 640.6 ± 215.4 708.7 ± 241.9 < 0.01
sVCAM-1 at follow-up 638.4 ± 243.8 601.9 ± 192.6 567.7 ± 162.7 618.7 ± 203.8 769.6 ± 342.0 < 0.01
ap-Value was based on chi square or ANOVA.health education, well labeling, and installa-
tions of deep wells was initiated as previously
described (Chen Y et al. 2007). These efforts
have led to an increase of well switching and
changes in urinary arsenic among some indi-
viduals (Chen Y et al. 2007).
Well arsenic concentration was tested as
part of the parent HEALS study. Detailed
methods have been described elsewhere
(Ahsan et al. 2006a, 2006b; van Geen et al.
2002). Briefly, water samples from all
5,966 tube wells in the study area were col-
lected in 50-mL acid-washed tubes after the
well was pumped for 5 min (van Geen et al.
2002). Water arsenic concentrations were ana-
lyzed by graphite furnace atomic-absorption
spectrometry with a Hitachi Z-8200 system
(Hitachi, Tokyo, Japan) at the Lamont-
Doherty Earth Observatory of Columbia
University (van Geen et al. 2002). Detailed
information on well-use history was also col-
lected as part of the parent cohort study at
baseline (Ahsan et al. 2006a). On average, par-
ticipants in the present study had consumed
water from the baseline well for 9.1 years.
Therefore, we consider our assessment of well
arsenic concentration at baseline to be a good
measure of long-term historical measure of
arsenic exposure.
Plasma levels of sICAM-1 and sVCAM-1.
It has been suggested that levels of sICAM-1
and sVCAM-1 are largely unaffected by trans-
port conditions and are reproducible within
subjects over time (Flower et al. 2000; Pai
et al. 2002), and that serum and EDTA-
plasma samples give comparable results
(Flower et al. 2000). The intraclass correla-
tions for samples with time-to-processing up
to 36 hr are > 0.75 for sICAM-1, and > 0.60
for sVCAM-1 (Pai et al. 2002). Plasma levels
of sICAM-1 and sVCAM-1 were determined
by means of enzyme-linked immunosorbent
assays using commercial kits (R&D Systems,
Minneapolis, MN). The minimum detectable
levels for sICAM-1 and sVCAM-1 are 0.35
and 0.60 ng/mL, respectively. The maximum
intraassay and interassay precision, expressed
as coefﬁcient of variation (CV%), are 4.8 and
10, and 3.6 and 7.8, for sICAM-1 and
sVCAM-1, respectively. In epidemiologic
studies of biomarkers, a CV < 5% is consid-
ered ideal, whereas CVs up to 15% are often
acceptable (Tworoger and Hankinson
2006b). Baseline and follow-up samples from
the same participants were placed in the same
assay batches to avoid interassay variability
(Tworoger and Hankinson 2006a, 2006b).
Arsenic exposure status and treatment assign-
ments of vitamin E and selenium were
masked to laboratory personnel.
Statistical analysis. We first conducted
descriptive analyses to compare distributions
of demographic, lifestyle, and arsenic expo-
sure-related variables among participants in
quartiles of well arsenic concentration.
Multiple linear regression models were con-
ducted to evaluate a) the cross-sectional asso-
ciations of baseline arsenic exposure and levels
of sICAM-1 and sVCAM-1; and b) the asso-
ciations of baseline arsenic exposure, changes
in arsenic exposure, and antioxidant treat-
ments with changes in levels of sICAM-1 and
sVCAM-1 from baseline to follow-up.
In cross-sectional analyses, baseline well
arsenic and urinary arsenic were entered in the
models alternatively, and we adjusted for age,
sex, body mass index (BMI), and smoking sta-
tus that may be predictors of levels of sICAM-1
and sVCAM-1 (Blankenberg et al. 2001;
Hwang et al. 1997; Ridker et al. 1998, 2000).
Previous studies from our group have suggested
that age, sex, BMI, and tobacco smoking may
modify health effects of arsenic toxicity (Ahsan
et al. 2006a; Chen Y et al. 2006b). For the
associations between baseline arsenic exposure
and changes in sICAM-1 and sVCAM-1, base-
line urinary and well arsenic were entered in the
model alternatively, and we additionally
adjusted for changes in urinary arsenic and
baseline level of sICAM-1 or sVCAM-1,
respectively. We also controlled for treatment
assignment in the models because the study was
a randomized trial of vitamin E and selenium.
For the associations with treatment regi-
men, we adjusted for age, sex, BMI, baseline
well arsenic, changes in urinary arsenic, and
baseline levels of sVCAM-1 or sICAM-1. We
also evaluated whether the severity of skin
lesions was related to baseline levels and
changes in levels of sVCAM-1 or sICAM-1.
Participants with melanosis only were com-
pared with those with both melanosis and
hyperkeratosis, controlling for the same
above-mentioned variables.
Arsenic exposure variables were catego-
rized based on quartiles. We computed least
squares means of sICAM-1 and sVCAM-1
according to the categories. In addition,
arsenic exposure variables were entered in the
models as continuous variables. Models were
also run with log-transformed sICAM-1 and
sVCAM-1; the results were similar and are
therefore not shown. All statistical analyses
were performed using the SAS 9.1.3 statistical
package for Windows (SAS Institute Inc.,
Cary, NC).
Results
The study population in general had a low
educational level and consisted of mostly
middle-aged men (Table 1). A total of 48.7%
of the participants were current smokers.
Well arsenic was not associated with duration
of well use, sex, smoking status, age, BMI,
educational attainment, treatment duration,
treatment assignment, urinary arsenic at fol-
low-up, or changes in urinary arsenic. Similar
to what was observed in the parent cohort
study (Ahsan et al. 2006a; Chen Y et al.
2007), well arsenic was positively related to
baseline urinary arsenic (p < 0.01) and switch-
ing to alternative wells (p < 0.02). In addition,
the proportion of participants with both
melanosis and hyperkeratosis, a later stage of
skin lesion, differed according to well arsenic
levels (p < 0.01). In univariate analyses, well
arsenic was positively related to plasma levels
of sVCAM-1 at both baseline and follow-up,
and to plasma levels of sICAM-1 at follow-up
but not at baseline.
The cross-sectional associations of arsenic
exposure with levels of sVCAM-1 and
sICAM-1 at baseline are presented in Table 2.
Baseline well arsenic was positively associated
Arsenic exposure and cell adhesion molecules
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Table 2. Associations of arsenic exposure variables and skin lesion types with baseline plasma levels of
sVCAM-1 and sICAM-1.
sVCAM-1 (ng/mL) sICAM-1 (ng/mL) 
Adj mean/ Adj mean/
regression regression
Variables Meana No. coefﬁcientb,c SD p-Value coefﬁcientb,c SD p-Value
Baseline well arsenic (µg/L)
3–96 52.7 29 644.4 45.6 411.2 25.1
97–230 158.2 29 667.4 46.8 423.4 25.8
231–381 320.2 29 745.4 51.5 429.3 28.4
382–864 566.5 28 788.1 48.1 443.3 26.5
Per µg/Lc 115 0.33 0.09 < 0.01 0.10 0.05 0.04
Baseline urinary arsenic (µg/g creatinine)
51–135 100.5 28 715.9 50.6 394.8 26.5
136–211 172.1 29 644.1 48.1 410.8 25.2
212–448 297.4 30 706.4 48.3 419.6 25.3
449–1,126 784.3 28 752.5 49.5 469.5 25.9
Per µg/g creatininec 115 0.04 0.07 0.53 0.10 0.04 < 0.01
Baseline skin lesion types
Melanosis only 72 681.1 39.9 417.7 21.86
Hyperkeratosis and melanosis 43 733.1 43.6 0.15 426.0 23.90 0.89
Adj, adjusted.
aCategory-speciﬁc mean values of the arsenic variables in the left column. bMeans of sVCAM-1 and sICAM-1 for arsenic
exposure categories were adjusted for sex, age, BMI, and smoking status; means for skin lesion categories were
adjusted for sex, age, BMI, smoking status, and baseline well arsenic. cRegression coefﬁcients and p-values were com-
puted with the arsenic exposure variable entered as a continuous variable in the model.with both baseline sVCAM-1 and sICAM-1
levels and more strongly with sVCAM-1 (p for
trend < 0.01), with increasing values in increas-
ing well arsenic quartiles. Every 1-µg/L increase
in baseline well arsenic was associated with an
increase of 0.10 ng/mL (95% CI, 0.00–0.20)
and 0.33 ng/mL (95% CI, 0.15–0.51) in
sICAM-1 and sVCAM-1, respectively, at base-
line. The associations remained significant
with additional adjustment for skin lesion
stages [0.10 (95% CI, 0.00–0.20) and 0.28
(95% CI, 0.09–0.46), respectively]. Baseline
urinary arsenic was also positively associated
with sICAM-1 and sVCAM-1 at baseline;
however, only the association with sICAM-1
was significant (p for trend < 0.01). Every
1-µg/g creatinine increase in baseline urinary
arsenic was associated with an increase of
0.10 ng/mL (95% CI, 0.03–0.17) in sICAM-1
at baseline. The association remained similar
with additional adjustment for skin lesion
stages [0.10 (95% CI, 0.03–0.16)].
Baseline well arsenic was positively related
to changes in plasma levels in sICAM-1 and
sVCAM-1, adjusting for age, sex, BMI, smok-
ing status, changes in urinary arsenic, and base-
line levels of sICAM-1 and sVCAM-1,
respectively (Table 3). Every 1-µg/L increase in
baseline well arsenic was associated with a rise
of 0.11 ng/mL (95% CI, 0.01–0.22) and
0.17 ng/mL (95% CI, 0.00–0.35) in sICAM-1
and sVCAM-1, respectively, from baseline to
follow-up. These associations also remained
similar after additional adjustment for skin
lesion stages [0.09 (95% CI, 0.01–0.20) and
0.15 (95% CI, 0.00–0.32), respectively]. The
positive associations appear to be driven by the
increases of sICAM-1 and sVCAM-1 in per-
sons with high baseline well arsenic. Among
those in the top quartile of baseline well
arsenic, we observed an increase of 55.5 and
97.1 ng/mL in sICAM-1 and sVCAM-1,
respectively, from baseline to follow-up.
Similarly, baseline urinary arsenic was posi-
tively related to changes in sICAM-1 and
sVCAM-1. Every 1-µg/g creatinine increase in
baseline urinary arsenic was associated with a
rise of 0.11 ng/mL (95% CI, 0.04–0.18) and
0.12 ng/mL (95% CI, 0.00–0.24) in sICAM-1
and sVCAM-1, respectively, from baseline to
follow-up. Again, these associations remained
similar with additional adjustment for skin
lesion stages [0.12 (95% CI, 0.05–0.19) and
0.11 (95% CI, 0.00–0.23)]. The association
between baseline urinary arsenic and the
increase in sVCAM-1 appears to be dose
response, with greater increases of plasma
sVCAM-1 observed at higher quartiles of uri-
nary arsenic. The higher three quartiles of uri-
nary arsenic were associated with a similar
increase in plasma sICAM-1. Stages of skin
lesions were not associated with the baseline
levels of sVCAM-1 and sICAM-1. Changes in
urinary arsenic, on the other hand, were not
associated with changes in sICAM-1 (Table 3).
Although the top quartile of change in urinary
arsenic, in which urinary arsenic increased by
124.5 µg/g creatinine, was associated with a
greater increase in sVCAM-1 than in other
quartiles, the overall trend was not signiﬁcant.
Treatment with selenium and vitamin E,
whether considered independently or jointly in
the analysis, was not related to changes in
either sVCAM-1 or sICAM-1. Stages of skin
lesions were not related to changes in levels of
sVCAM-1 and sICAM-1.
Discussion
We observed positive associations of well
arsenic concentration, a long-term arsenic
exposure measure in the present study, with
plasma levels of sVCAM-1 and sICAM-1.
The association was consistent in both cross-
sectional and longitudinal analyses. However,
short-term changes in arsenic exposure
(defined as changes in urinary arsenic) and
short-term treatment with selenium and vita-
min E over 6 months were not associated
with changes in plasma levels of sVCAM-1
and sICAM-1 during the same period. To
our knowledge, the present study is the ﬁrst
epidemiologic study that evaluates the associ-
ations between arsenic exposure and circulat-
ing levels of sVCAM-1 and sICAM-1.
sICAM-1, and sVCAM-1 are markers of
vascular inflammation and endothelial dys-
function that are detectable in the circulation.
ICAM-1 is a member of the immunoglobulin
protein superfamily that mediates cell–cell
adhesion (Heiska et al. 1998). Adhesion of
circulating leukocytes to the endothelial cell
and subsequent transendothelial migration is
an important step in the initiation of athero-
sclerosis (Ross 1993). In part, this process is
mediated by cellular adhesion molecules
(Adams and Shaw 1994; Cybulsky and
Gimbrone 1991), which are expressed on the
endothelial membrane in response to inﬂam-
matory stimuli. Several large prospective epi-
demiologic studies have found a significant
positive association between increasing serum
or plasma concentration of sICAM-1 and
Chen et al.
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Table 3. Associations of arsenic exposure variables, skin lesion types, and antioxidant treatments with
changes in plasma levels of sVCAM-1 and sICAM-1 from baseline to follow-up.
Changes from baseline to follow-up
sVCAM-1 (ng/mL) sICAM-1 (ng/mL) 
Adj mean/ Adj mean/
regression regression
Meana No. coefﬁcientb,c SD p-Value coefﬁcientb,c SD p-Value
Baseline well arsenic (µg/L)
3–96 52.7 29 18.3 41.5 15.4 26.5
97–230 158.2 29 –21.0 43.8 –9.9 28.1
231–381 320.2 29 26.2 48.6 0.9 30.5
382–864 566.5 28 97.1 46.0 55.5 28.3
Per µg/Lc 115 0.17 0.09 0.05 0.11 0.05 0.03
Baseline urinary arsenic (µg/g creatinine)
51–135 100.5 28 –3.5 48.0 8.3 30.3
136–211 172.1 29 16.3 44.7 22.7 28.4
212–448 297.4 30 48.1 44.5 20.3 28.0
449–1,126 784.3 28 68.0 61.3 19.5 38.2
Per µg/g creatininec  115 0.12 0.06 0.05 0.11 0.04 < 0.01
Changes in urinary arsenic (µg/g creatinine)
–1,062 to –145 –314.6 29 19.4 19.4 31.9 26.5
–144 to –41 –80.7 28 20.5 20.5 2.4 29.0
–40 to –4 –22.6 29 25.6 25.6 9.6 29.6
–3 to 288 124.5 29 55.1 55.1 18.1 29.4
Per µg/g creatininec 115 –0.04 0.06 0.56 –0.03 0.06 0.12
Baseline skin lesion types
Melanosis only 72 12.6 35.3 10.7 22.50
Hyperkeratosis and melanosis 43 64.2 40.1 0.13 28.9 25.28 0.30
Treatment assignment
No selenium 57 18.0 38.9 2.5 24.5
Selenium 58 42.3 35.3 0.49 28.4 21.9 0.24
No vitamin E 58 48.6 39.3 11.2 24.6
Vitamin E 57 11.7 35.3 0.30 19.7 22.2 0.71
Placebo 29 23.4 46.5 –2.2 29.4
Selenium only 28 80.2 46.4 24.9 29.4
Vitamin E only 29 16.2 44.8 7.3 28.5
Vitamin E and selenium 29 7.6 41.3 0.49 32.0 26.0 0.68
Adj, adjusted.
aCategory-speciﬁc mean values of the arsenic variables in the left column. bMeans of sVCAM-1 and sICAM-1 for arsenic
exposure categories were adjusted for sex, age, BMI, smoking status, treatment regimen, and baseline levels of
sVCAM-1 (for changes in sVCAM-1) or sICAM-1 (for changes in sICAM-1); adjusted means for baseline urinary or well
arsenic categories were also adjusted for changes in urinary arsenic. Adjusted means for treatment regimen and skin
lesion categories were adjusted for sex, age, BMI, smoking status, baseline well arsenic, changes in urinary arsenic, and
baseline levels of sVCAM-1 (for changes in sVCAM-1) or sICAM-1 (for changes in sICAM-1). cRegression coefﬁcients and
p-values were computed with the arsenic exposure variable entered as a continuous variable in the model.risks of total cardiovascular events (Ridker
et al. 2000), myocardial infarction (Ridker
et al. 1998), and carotid artery athero-
sclerosis (Hwang et al. 1997). More recently,
sICAM-1 has also been associated with a risk
of diabetes in prospective cohort studies
(Meigs et al. 2004; Song et al. 2007).
Development of CVD is the principal com-
plication in type 2 diabetes (Fuller et al.
1983; Jeerakathil et al. 2007; Kannel and
McGee 1979). Our finding of the positive
association between arsenic exposure and
sICAM-1 supports that diabetes and CVD
share common antecedents that may be
affected by arsenic exposure.
VCAM-1 binds to very late antigen-4, an
integrin expressed by monocytes, lympho-
cytes, and eosinophils; this interaction pro-
motes firm cell–cell adhesion and eventual
transmigration of inflammatory cells
(Cybulsky and Gimbrone 1991). However,
plasma levels of sVCAM-1 have not been
reported to be predictive of future CVD risk
among apparently healthy individuals
(de Lemos et al. 2000; Hwang et al. 1997).
In contrast, in persons with previous docu-
mented coronary artery disease, elevated
plasma sVCAM-1 was associated with future
death from CVD, independent of all other
inﬂammatory and soluble adhesion markers
(Blankenberg et al. 2001). ICAM-1 is
expressed by many cells of hemotopoietic
lineage and ﬁbroblasts and thus may be a less
specific marker than VCAM-1, which is
mainly expressed on atherosclerotic plaques
by activated endothelial cells and smooth
muscle cells (Blake and Ridker 2002). The
positive associations of well arsenic with
baseline and changes in plasma sVCAM-1
and sICAM-1 suggest a potential pathway
underlying the effect of long-term arsenic
exposure on CVD.
In the present study, changes in urinary
arsenic over 6 months were not related 
to changes in sVCAM-1 and sICAM-1.
Similarly, treatment with selenium and vita-
min E during the same period did not modu-
late levels of sVCAM-1 and sICAM-1,
although experimental studies have suggested
that selenium and vitamin E treatment may
inhibit the expression of VCAM-1 and
ICAM-1 (Koga et al. 2004; Zhang et al.
2002). Our ﬁndings on the effect of vitamin
E supplementation are consistent with short-
term trials in smokers, postmenopausal
women, and patients with diabetes that did
not ﬁnd signiﬁcant effect of vitamin E supple-
mentation alone on these markers (Koh et al.
1999; Tousoulis et al. 2003; Upritchard et al.
2000). On the other hand, high levels of base-
line well arsenic and baseline urinary arsenic,
which were signiﬁcantly correlated with base-
line well arsenic, were related to increases in
sVCAM-1 and sICAM-1 over time. In the
present study, participants had consumed
water from the baseline wells for an average of
9 years. Taken together, the ﬁndings suggest
that the effect of high-level, long-term arsenic
exposure on vascular inflammation and
endothelial dysfunction persists over time in
spite of short-term changes in exposure level
and antioxidant treatment. In a prospective
case–cohort study of risk of arsenic-related
skin lesions nested in the same parent cohort
study, we also observed that high levels of
baseline well arsenic were predictive of inci-
dence of arsenic-related skin lesions, regardless
of changes in exposure level over 2 years (Hall
et al. 2006). Additional studies are needed to
assess whether long-term changes in arsenic
exposure and long-term selenium and
vitamin E supplementation could influence
subsequent changes in levels of sVCAM-1 and
sICAM-1 and risk of other health effects
related to arsenic exposure.
The ﬁndings of the present study should
be interpreted with caution. First, the study
population consists of mostly men and smok-
ers with skin lesions. The results may not be
generalizable to nonsmokers, women, or per-
sons with no skin lesions. The literature and
our previous analyses have suggested that men
and cigarette smokers are more susceptible to
health effects of arsenic exposure (Ahsan et al.
2006b; Bates et al. 2004; Chen CL et al.
2004; Chen Y et al. 2006b; Ferreccio et al.
2000; Karagas et al. 2004). To the extent that
susceptibility to the effects of arsenic exposure
on levels of sVCAM-1 and sICAM-1 is associ-
ated with smoking and male sex, the observed
associations may differ from those in the over-
all population in the study area. Cutaneous
abnormalities are well-known early signs of
chronic arsenic poisoning and may lead to
arsenic-related skin cancer. However, no stud-
ies have suggested that persons with skin
lesions are more or less likely to develop
CVD, apart from the fact that they may have
a higher level of arsenic exposure. The
observed positive association between arsenic
exposure and sVCAM-1 and sICAM-1 is not
likely a consequence of skin lesions because
there was no association between the severity
of skin lesions and plasma levels of sVCAM-1
and sICAM-1. Additional adjustment for skin
lesion stages in the models did not change the
effect estimates appreciably. Second, because
the sample size was small and the arsenic
exposure levels in persons with skin lesions
were high, we were not able to conduct
detailed analyses to evaluate effects of arsenic
exposure < 100 µg/L. Future large studies are
required to study the associations of low-level
arsenic exposure with markers of vascular
inﬂammation and endothelial dysfunction in
healthy persons.
Strengths of this study include the avail-
ability of multiple arsenic exposure measures
to study long-term and recent changes of
exposure, the prospective nature of the longi-
tudinal analysis, the random assignment of
antioxidant treatments, and the large variation
in exposure level in the study population. In
summary, we found positive associations of
well arsenic concentration with plasma levels
of sVCAM-1 and sICAM-1 in persons with
skin lesions, suggesting the effect of chronic
arsenic exposure on inflammation and
endothelial dysfunction. Future studies are
needed to confirm the associations in other
populations.
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